Article content
The Ottawa Hospital has become one of only two sites in Ontario to offer an expensive, cutting-edge treatment to patients with aggressive forms of non-Hodgkin lymphoma.
The availability of the new CAR T-cell therapy — a personalized form of immunotherapy — offers new hope to patients previously offered only palliative care.
We apologize, but this video has failed to load.
Try refreshing your browser, or
Patients with aggressive blood cancers given "transformative option" for treatment Back to video
“This really is a paradigm shift in cancer care,” said Dr. Michael Kennah, a hematologist at The Ottawa Hospital.
The new therapy, marketed under the brand name Yescarta, is the second chimeric antigen receptor (CAR) T-cell therapy to be approved for use in Ontario.